Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer

NCT01661790 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

72

Enrollment

OTHER

Sponsor class

Conditions

Malignant Pleural Effusion

Interventions

DRUG: Bevacizumab
DRUG: Cisplatin

Sponsor

Chinese PLA General Hospital

Collaborators

[object Object]